摘要
目的培美曲塞是新一代的抗肿瘤药物,但其在肺癌治疗中的耐药现象日益明显,建立耐培美曲塞人肺腺癌细胞株A549/Pemetrexed有利于对培美曲塞耐药的深入研究。方法以人肺腺癌细胞株A549为亲代细胞,采用"血浆峰浓度冲击与逐步增加剂量相结合诱导"法,用培美曲塞进行诱导,建立耐培美曲塞细胞株A549/Pemetrexed,测定其生长曲线、倍增时间和克隆增长率,并与A549相比较。结果 A549/Pemetrexed对培美曲塞的耐药指数为(14.81±1.47),并对吉西他滨、5氟脲嘧啶、顺铂、卡铂耐药,耐药指数分别为(9.20±2.65)、(12.2±1.79)、(5.79±0.68)、(7.98±1.02);对紫杉醇、多西他赛敏感,耐药指数分别为(1.44±0.34)、(1.04±0.21);增殖速度与A549接近,分别为(63.03±0.98)h和(62.63±1.23)h。结论本研究建立的A549/Pemetrexed细胞株生长稳定,可用于下游的实验研究。
Objective Pemetrexed is a new drug for cancer,but the resistance to this agent in lung cancer is becoming more and more obvious.This study was to establish a human pemetrexed-resistant non-small-cell lung cancer cell line A549/pemetrexed to achieve a further insight into the resistance to pemetrexed.Methods Human pemetrexed-resistant non-small-cell lung cancer cell line A549/pemetrexed was established by repeated serous peak concentration and then low but gradually increasing concentration of pemetrexed from its parental cell human lung adenocarcinoma cell line A549.During the inducement,the resistance index of pemetrexed was determined by MTT,its growth curve obtained,its doubling time calculated,and comparisons were made with A549.Results The resistance index of A549/pemetrexed to pemetrexed was 14.81±1.47.The cell line also exhibited cross-resistance to gemcitabine（9.20±2.65）,fluorouracil（12.2±1.79）,cisplatin（5.79±0.68） and carboplatin（7.98±1.02）,as well as to paclitaxol（1.44±0.34） and docetaxel（1.04±0.21）.Its proliferation rate was similar to that of A549.The doubling time of A549/pemetrexed was（63.03±0.98）h,as compared with that of A549（62.63±1.23）h.Conclusion Human pemetrexed-resistant non-small-cell lung cancer cell line A549/pemetrexed was established successfully,which can be used as an important tool for further study of the resistance to pemetrexed.
出处
《医学研究生学报》
CAS
北大核心
2012年第3期241-243,共3页
Journal of Medical Postgraduates
基金
江苏省卫生厅重大科研项目(H201023)
关键词
培美曲塞
耐药
非小细胞肺癌
Pemetrexed
Drug-resistance
Non-small-cell lung cancer
